Twitter Thread by Carrie



Carrie
@life_is_art___

I'd like to make a list of which ones and when they were put on the payroll from the attorneys. Also, others like Caleb Alexander and Tim Munson. Anyone that has had their hand in policy or publicly demonized pain meds and then profited off of litigation, get em on the list.

@JSG_54 Here's #ArtVanZee
https://t.co/a5QDnwR3vi

@JSG_54 #AnnaLembke

https://t.co/O4PCOmNjTl

@JSG_54 #DaneshMazloomdoost https://t.co/qCjiglbIgD

@JSG_54 #AndrewKolodny
https://t.co/Plx4VBoyIw's-closing-remarks-after-direct-examination-during-state-opioid

@JSG_54 #MarkSullivan #JaneBallantyne #AnnaLembke
https://t.co/Bw4AHitu05

1:22
restructuring.primeclerk.com

5. Dr. Jane Ballantyne
University of Washington School of Medicine
4225 Roosevelt Way NE, No. 401
Seattle, WA 98105
(206) 598-6647

Dr. Jane Ballantyne is a board certified anesthesiologist at t
Medical Center and a University of Washington professor (retired)
Medicine and Director of the University of Washington Pain Fellowsh
o testify regarding her opinions about pain medicine, pain
epresentations regarding the risks and benefits of opioids for chronic

The grounds for Dr. Ballantyne's opinions include her educat
skill. Dr. Ballantyne also relies on her academic, professional, and c
f pain medicine. Her opinions are further based on her review of
tudies, and reports.

6. Dr. Mark Sullivan
University of Washington
Department of Psychiatry & Behavioral Sciences
Box 356560
Seattle, WA 98195-6560
(206) 685-3184
sullimar@uw.edu

Dr. Mark Sullivan is an Adjunct Professor of Bioethics and Hu
nd Pain Medicine at the University of Washington. Dr. Sullivan is
pinions related to pain medicine, addiction, and Purdue's represent
ddiction in its marketing and promotion of opioids.

The grounds for Dr. Sullivan's opinions include his educati
skill. Dr. Sullivan also relies on his academic experience and r
nedicine and on the topic of opioid therapy for chronic pain, and
pinions are further based on his review of relevant documents, art

7. Dr. Anna Lembke
Stanford University Medical Center
Psychiatry Department
401 Quarry Rd, Rm 2303, MC 5723
Stanford, CA 94305
(650) 725-9570
alembke@stanford.edu

@JSG_54 #GaryFranklin

https://t.co/4o23WkWRS8

@JSG_54 #AdrianeFughBerman https://t.co/Pby0Adpjso

Main article: Opioid crisis

Georgetown University Medical Center professor, Fugh-Berman, served as a paid expert witness in the lawsuit filed in 2017 by the State of Oklahoma against 13 major pharmaceutical companies for "damages linked to the opioid crisis. According to the original 2017 petition, Oklahoma said the sale of Oxycontin, by its manufacturer, Purdue Pharma, from 1996 to 2009, rose from $48 million to $3 billion.[3] According to a March 26, 2019 PBS News article, Fugh-Berman who works out of the University's Department of Pharmacology and Physiology, said that over time, "industry-generated narrative [became] conventional wisdom". PBS News wrote that "these deadly consequences didn't happen overnight". Fugh-Berman said that the industry used "pervasive marketing tactics" to "influence conversations" between "patients", "doctors, medical school students and instructors". The article said that "One tactic that opioid manufacturers used to protect sales was the rebranding of substance use disorder as pseudo addiction — that patients who took opioid medication and later developed symptoms of addiction should be treated with more opioids. According to the *PBS News* March 2019 article, even though

@JSG_54 Steve Gelfand https://t.co/0B24Q2KS8y

2:59

AA patch.com

Greater Hartford, CT + Follow

News Feed Neighbor Posts Classifieds Calendar

Surviving Virus

Health & Fitness

Possible Deadline Extension For CT Claims Against Purdue Pharma

Connecticut's Attorney General has asked the court overseeing the Purdue Pharma bankruptcy to extend the deadline for filing claims.

Press Release Desk, News Partner
Posted Sat, May 23, 2020 at 2:51 pm ET

Reply

Press release from the Office of the Attorney General, Connecticut:

ADVERTISEMENT

@JSG_54 @threadreaderapp unroll